Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
5
×
national blog main
clinical trials
biotech
boston blog main
boston top stories
fda
san diego blog main
san francisco blog main
boston
drugs
dyne therapeutics
myotonic dystrophy type 1
national top stories
new york blog main
rare disease drugs
san diego top stories
san francisco
san francisco top stories
akcea therapeutics
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech ipos
bluebird bio
cannabidiol
cardiomyopathy
deals
dravet syndrome
duchenne muscular dystrophy
epidiolex
facioscapulohumeral muscular dystrophy
fen-phen
fenfluramine
food and drug administration
gene therapy
gw pharmaceuticals
inotersen
What
drug
rare
5
×
ago
genetic
medicines
therapeutics
approved
battle
data
disease
dyne
fda
ipo
muscle
sets
akcea
alnylam
amyloidosis
attr
available
biotechs
brings
building
cannabis
company
considering
deal
debilitating
derivative
developer
developing
diseases
disorders
dyne’s
early
epilepsy
established
expected
experimental
eyes
Language
unset
Current search:
rare
×
" life sciences "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed